Search results

Selected filters:

Law & Policy
North America

Article type

Topic

Sector

Jurisdictions

467 results found for your search

Sort options
18 February 2019

Rolling the dice on eligibility

Congressional action is the only way to solve the uncertainty on section 101 of the US patent statute, argues Aaric Eisenstein of Personalised Media Communications

14 February 2019

As 101 debate continues, Iancu offers clear message to Federal Circuit

With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent

13 February 2019

IPBC Global 2019 is shaping up to be the biggest and best of the series so far

Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco 

08 February 2019

US patent system jumps to second in the world, though the biopharma sector may not agree

PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies

05 February 2019

USPTO rules on patent term adjustment set to change following CAFC decision

The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences

01 February 2019

We have not been informed of any Chinese antitrust investigation of us, Ericsson tells <em>IAM</em>

Swedish company issues statement after an unsourced Chinese media article claims that a probe into its licensing practices is underway

31 January 2019

The pharma fightback

Brand name pharmaceutical companies are facing a policy-making onslaught; with their IP strategies firmly in the spotlight, many are being forced to speak up for the rights that underpin their products.

31 January 2019

Pressure piles on US pharma and biotech IP owners

America's life sciences innovators face accusations of using patents to build monopolies and overcharge for vital medicines. If they do not tell their side of the story and fast, they risk losing vital protections on which they rely   

25 January 2019

Treat IP rights as property to maximise their value, Huawei CEO urges

In a rare public appearance, the Chinese telecom’s founder and CEO, Ren Zhengfei, reaffirms commitment to respect third-party patents and explains why paying more than the competition will keep his company ahead

23 January 2019

Kokes hails "fantastic first year" as NantWorks CIPO

In exclusive interview with IAM, after confirming as a speaker for IPBC Global 2019, the former BlackBerry IP chief talks in-depth about life sciences and high tech convergence - and the many patent opportunities that creates 

23 January 2019

Welcome to the future of patents

New IAM research reports identify the key trends shaping the global IP market – and tell you how to respond

22 January 2019

Despite its potential appeal to patent owners don’t expect a litigation stampede to Waco

Appointment of experienced patent litigator to local bench and Austin's growing reputation as a tech hub must be weighed against defendant-friendly rules

18 January 2019

The clock is ticking as US government shutdown threatens to cause major pharma patent disruption

Services at the FDA could “grind to a halt” in a matter weeks if the budget deadlock between President Trump and Democrats continues. Major disruption at the USPTO and in the courts may also be on the cards.

18 January 2019

Downward trend in US patent litigation continues; Big Tech gets busier at the PTAB

Lawsuit filings and inter partes review petitions both fell in 2018, but operating companies’ share of the action was on the rise 

11 January 2019

Readiness to arbitrate with Huawei demonstrates InterDigital's FRAND intentions, CEO says

In exclusive interview with IAM, Bill Merritt claims that ADR can prevent current licence conflict with Huawei becoming a flashpoint in the US-China trade battle